表紙
市場調査レポート

血小板減少症:パイプライン製品の分析

Thrombocytopenia - Pipeline Review, H1 2016

発行 Global Markets Direct 商品コード 232814
出版日 ページ情報 英文 178 Pages
即納可能
価格
本日の銀行送金レート: 1USD=101.32円で換算しております。
Back to Top
血小板減少症:パイプライン製品の分析 Thrombocytopenia - Pipeline Review, H1 2016
出版日: 2016年05月18日 ページ情報: 英文 178 Pages
概要

血小板減少症は、血小板数の異常な減少が特徴です。原因として、骨髄中の血小板の生産減少、脾臓または肝臓の血流中の血小板の破壊亢進などが挙げられます。口内・歯茎の出血、あざ、鼻血、発疹などの症状が見られます。治療は、止血または出血の予防として、血小板の輸血が行われます。

当レポートでは、血小板減少症に対する治療薬の開発状況について調査分析し、パイプライン製品の概要、治験の段階別の製品の概要、主要企業プロファイル、薬剤のプロファイル、パイプライン製品の最新動向、最新ニュースとプレスリリースなどについて、体系的な情報を提供しています。

イントロダクション

  • 調査範囲

血小板減少症の概要

治療薬の開発

  • パイプライン製品の概要
  • パイプライン製品の比較分析

血小板減少症:企業で開発中の治療薬

血小板減少症:大学/機関で研究中の治療薬

血小板減少症:パイプライン製品の概況

  • 後期段階の製品
  • 臨床段階の製品
  • 初期段階の製品

血小板減少症:企業で開発中の製品

血小板減少症:大学/機関で研究中の製品

血小板減少症の治療薬開発に従事している企業

  • 3SBio Inc.
  • Amarillo Biosciences, Inc.
  • Amgen Inc.
  • Baxalta Incorporated
  • Bayer AG
  • BioLineRx, Ltd.
  • Boehringer Ingelheim GmbH
  • Bolder Biotechnology, Inc.
  • Bristol-Myers Squibb Company
  • Cellerant Therapeutics, Inc.
  • エーザイ
  • Genosco
  • Hansa Medical AB
  • Immunomedics, Inc.
  • Intas Pharmaceuticals Ltd.
  • Jiangsu Hengrui Medicine Co., Ltd.
  • Merck & Co., Inc.
  • Momenta Pharmaceuticals, Inc.
  • Myelo Therapeutics GmbH
  • Neumedicines Inc.
  • Novartis AG
  • Pfizer Inc.
  • PhytoHealth Corporation
  • Prophylix Pharma AS
  • Protalex, Inc.
  • Rigel Pharmaceuticals, Inc.
  • 塩野義製薬
  • STATegics, Inc.
  • UCB S.A.
  • ViroMed Co., Ltd.

血小板減少症:治療薬の評価

  • 単剤製品
  • 標的別
  • 作用機序別
  • 投与経路別
  • 分子タイプ別

薬剤プロファイル

血小板減少症:最近のパイプライン動向

血小板減少症:休止中のプロジェクト

血小板減少症:開発が中止された製品

血小板減少症:製品開発のマイルストーン

  • 主なニュースとプレスリリース

付録

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC8023IDB

Summary

Global Markets Direct's, 'Thrombocytopenia - Pipeline Review, H1 2016', provides an overview of the Thrombocytopenia pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Thrombocytopenia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Thrombocytopenia and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Thrombocytopenia
  • The report reviews pipeline therapeutics for Thrombocytopenia by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Thrombocytopenia therapeutics and enlists all their major and minor projects
  • The report assesses Thrombocytopenia therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Thrombocytopenia

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Thrombocytopenia
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Thrombocytopenia pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Thrombocytopenia Overview
    • Therapeutics Development
  • Pipeline Products for Thrombocytopenia - Overview
  • Pipeline Products for Thrombocytopenia - Comparative Analysis
  • Thrombocytopenia - Therapeutics under Development by Companies
  • Thrombocytopenia - Therapeutics under Investigation by Universities/Institutes
  • Thrombocytopenia - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
  • Thrombocytopenia - Products under Development by Companies
  • Thrombocytopenia - Products under Investigation by Universities/Institutes
  • Thrombocytopenia - Companies Involved in Therapeutics Development
    • 3SBio Inc.
    • Amarillo Biosciences, Inc.
    • Amgen Inc.
    • Baxalta Incorporated
    • Bayer AG
    • BioLineRx, Ltd.
    • Boehringer Ingelheim GmbH
    • Bolder Biotechnology, Inc.
    • Bristol-Myers Squibb Company
    • Cellerant Therapeutics, Inc.
    • Eisai Co., Ltd.
    • Genosco
    • Hansa Medical AB
    • Immunomedics, Inc.
    • Intas Pharmaceuticals Ltd.
    • Jiangsu Hengrui Medicine Co., Ltd.
    • Merck & Co., Inc.
    • Momenta Pharmaceuticals, Inc.
    • Myelo Therapeutics GmbH
    • Neumedicines Inc.
    • Novartis AG
    • Pfizer Inc.
    • PhytoHealth Corporation
    • Prophylix Pharma AS
    • Protalex, Inc.
    • Rigel Pharmaceuticals, Inc.
    • Shionogi & Co., Ltd.
    • STATegics, Inc.
    • UCB S.A.
    • ViroMed Co., Ltd.
  • Thrombocytopenia - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • Antibody for Autoimmune Disorders and Inflammation - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • avatrombopag - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • BBT-059 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • BI-655064 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • BL-8040 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • BMS-986004 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • CLT-009 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • eltrombopag olamine - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • eltrombopag olamine - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • fostamatinib disodium - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • GL-2045 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • GSK-2285921 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Hetrombopag Olamine - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • interferon alfa - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • lusutrombopag - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • MK-8723 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Monoclonal Antibody to Agonize TpoR for Thrombocytopenia - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Monoclonal Antibody to Antagonize FcgR1 for Inflammatory and Autoimmune Disorders - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Monoclonal Antibody to Antagonize FcgRIIa for Inflammatory and Autoimmune Disorders - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Myelo-001 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • NMIL-121 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Oligonucleotides to Activate miRNA-150 for Thrombocytopenia and Anemia - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • PBF-1509 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • PEG-VM501 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • PHN-013 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • PRTX-100 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Recombinant Enzyme to Inhibit Immunoglobulin G for Autoimmune Diseases - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • rivaroxaban - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • romiplostim - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • romiplostim biosimilar - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • SKIO-703 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • SM-101 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules to Inhibit BLVRB for Thrombocytopenia - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules to Inhibit PF4 for Heparin Induced Thrombocytopenia - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • STST-4 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • thrombopoietin - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Tromplate - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • TXA-302 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • UCB-7665 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • veltuzumab - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Thrombocytopenia - Recent Pipeline Updates
  • Thrombocytopenia - Dormant Projects
  • Thrombocytopenia - Discontinued Products
  • Thrombocytopenia - Product Development Milestones
    • Featured News & Press Releases
      • Apr 19, 2016: Nplate (Romiplostim) Study In The Lancet Shows Significant Increase In Durable Platelet Response Among Children With Immune Thrombocytopenia
      • Apr 07, 2016: Novartis receives EU approval for Revolade as first-in-class therapy for children aged 1 year and above with chronic ITP
      • Apr 01, 2016: Rigel Completes Enrollment of FIT Phase 3 Program for Fostamatinib in ITP
      • Jan 29, 2016: CHMP adopts extension to existing therapeutic indication for eltrombopag
      • Jan 28, 2016: Rigel Completes Enrollment of First Phase 3 Study of Fostamatinib in ITP
      • Jan 07, 2016: Rigel Reviews Recent Progress and Announces Presentation at the 34th Annual J.P. Morgan Healthcare Conference in San Francisco
      • Dec 01, 2015: Shionogi Launches MULPLETA Tablets 3mg In Japan for Improvement of Thrombocytopenia
      • Sep 28, 2015: Shionogi Receives Marketing and Manufacturing Approval in Japan for MULPLETA Tablets 3mg for Improvement of Thrombocytopenia
      • Sep 08, 2015: Rigel Granted Orphan Drug Designation for Fostamatinib in ITP
      • Sep 04, 2015: Xarelto Lawsuit Funding Firm, Fair Rate Funding Reports a Steady Rise in Xarelto Product Liability Lawsuit Filings
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Thrombocytopenia, H1 2016
  • Number of Products under Development for Thrombocytopenia - Comparative Analysis, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Number of Products under Development by Companies, H1 2016 (Contd..1)
  • Number of Products under Investigation by Universities/Institutes, H1 2016
  • Comparative Analysis by Late Stage Development, H1 2016
  • Comparative Analysis by Clinical Stage Development, H1 2016
  • Comparative Analysis by Early Stage Development, H1 2016
  • Products under Development by Companies, H1 2016
  • Products under Development by Companies, H1 2016 (Contd..1)
  • Products under Development by Companies, H1 2016 (Contd..2)
  • Products under Investigation by Universities/Institutes, H1 2016
  • Thrombocytopenia - Pipeline by 3SBio Inc., H1 2016
  • Thrombocytopenia - Pipeline by Amarillo Biosciences, Inc., H1 2016
  • Thrombocytopenia - Pipeline by Amgen Inc., H1 2016
  • Thrombocytopenia - Pipeline by Baxalta Incorporated, H1 2016
  • Thrombocytopenia - Pipeline by Bayer AG, H1 2016
  • Thrombocytopenia - Pipeline by BioLineRx, Ltd., H1 2016
  • Thrombocytopenia - Pipeline by Boehringer Ingelheim GmbH, H1 2016
  • Thrombocytopenia - Pipeline by Bolder Biotechnology, Inc., H1 2016
  • Thrombocytopenia - Pipeline by Bristol-Myers Squibb Company, H1 2016
  • Thrombocytopenia - Pipeline by Cellerant Therapeutics, Inc., H1 2016
  • Thrombocytopenia - Pipeline by Eisai Co., Ltd., H1 2016
  • Thrombocytopenia - Pipeline by Genosco, H1 2016
  • Thrombocytopenia - Pipeline by Hansa Medical AB, H1 2016
  • Thrombocytopenia - Pipeline by Immunomedics, Inc., H1 2016
  • Thrombocytopenia - Pipeline by Intas Pharmaceuticals Ltd., H1 2016
  • Thrombocytopenia - Pipeline by Jiangsu Hengrui Medicine Co., Ltd., H1 2016
  • Thrombocytopenia - Pipeline by Merck & Co., Inc., H1 2016
  • Thrombocytopenia - Pipeline by Momenta Pharmaceuticals, Inc., H1 2016
  • Thrombocytopenia - Pipeline by Myelo Therapeutics GmbH, H1 2016
  • Thrombocytopenia - Pipeline by Neumedicines Inc., H1 2016
  • Thrombocytopenia - Pipeline by Novartis AG, H1 2016
  • Thrombocytopenia - Pipeline by Pfizer Inc., H1 2016
  • Thrombocytopenia - Pipeline by PhytoHealth Corporation, H1 2016
  • Thrombocytopenia - Pipeline by Prophylix Pharma AS, H1 2016
  • Thrombocytopenia - Pipeline by Protalex, Inc., H1 2016
  • Thrombocytopenia - Pipeline by Rigel Pharmaceuticals, Inc., H1 2016
  • Thrombocytopenia - Pipeline by Shionogi & Co., Ltd., H1 2016
  • Thrombocytopenia - Pipeline by STATegics, Inc., H1 2016
  • Thrombocytopenia - Pipeline by UCB S.A., H1 2016
  • Thrombocytopenia - Pipeline by ViroMed Co., Ltd., H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Number of Products by Stage and Target, H1 2016
  • Number of Products by Stage and Mechanism of Action, H1 2016
  • Number of Products by Stage and Route of Administration, H1 2016
  • Number of Products by Stage and Molecule Type, H1 2016
  • Thrombocytopenia Therapeutics - Recent Pipeline Updates, H1 2016
  • Thrombocytopenia - Dormant Projects, H1 2016
  • Thrombocytopenia - Dormant Projects (Contd..1), H1 2016
  • Thrombocytopenia - Dormant Projects (Contd..2), H1 2016
  • Thrombocytopenia - Discontinued Products, H1 2016

List of Figures

  • Number of Products under Development for Thrombocytopenia, H1 2016
  • Number of Products under Development for Thrombocytopenia - Comparative Analysis, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Comparative Analysis by Late Stage Development, H1 2016
  • Comparative Analysis by Clinical Stage Development, H1 2016
  • Comparative Analysis by Early Stage Products, H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Number of Products by Top 10 Targets, H1 2016
  • Number of Products by Stage and Top 10 Targets, H1 2016
  • Number of Products by Top 10 Mechanism of Actions, H1 2016
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016
  • Number of Products by Routes of Administration, H1 2016
  • Number of Products by Stage and Routes of Administration, H1 2016
  • Number of Products by Top 10 Molecule Types, H1 2016
  • Number of Products by Stage and Top 10 Molecule Types, H1 2016
Back to Top